ARTV
Bearish signalScored 2026-10-12 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Research, not advice.
À propos
Artiva Biotherapeutics, Inc.
- Nom
- Artiva Biotherapeutics, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $297.3M
- Employés
- 115
- PDG
- Fred Aslan
- Site web
- https://www.artivabio.com
- Marché
- ADVMALXOCNTBDTILGUTSIFRX
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 170 476 titres (~1 536 845,39 $ US)
- Insiders
- Aslan Fred
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$1,997,682
Avg sell (VWAP, 90d window) $9.13 vs last close $5.85 (-35.9%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$528,509 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-10-06
- Liquidity
- Thin $2,752,873/day · 20d vol
- Last synced
-
2026-10-16 21:10:08
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-06 | Aslan Fred | Sell · S · 10b5-1 | 23,463 | $7.20 | $168,880 | Form 4 |
| 2026-10-05 | Aslan Fred | Sell · S | 61,696 | $6.84 | $421,828 | Form 4 |
| 2026-10-05 | Banerjee Subhashis | Sell · S | 1,099 | $6.84 | $7,514 | Form 4 |
| 2026-10-05 | Bush Jennifer | Sell · S | 8,370 | $6.84 | $57,227 | Form 4 |
| 2026-10-05 | Horan Christopher | Sell · S | 10,340 | $6.84 | $70,697 | Form 4 |
| 2026-09-08 | Aslan Fred | Sell · S · 10b5-1 | 23,429 | $10.92 | $255,746 | Form 4 |
| 2026-09-03 | Aslan Fred | Sell · S | 61,888 | $11.16 | $690,392 | Form 4 |
| 2026-09-03 | Banerjee Subhashis | Sell · S | 1,100 | $11.16 | $12,271 | Form 4 |
| 2026-09-03 | Bush Jennifer | Sell · S | 8,391 | $11.16 | $93,606 | Form 4 |
| 2026-09-03 | Horan Christopher | Sell · S | 10,366 | $11.16 | $115,638 | Form 4 |
| 2026-08-27 | Banerjee Subhashis | Sell · S · 10b5-1 | 8,222 | $12.01 | $98,736 | Form 4 |
| 2026-08-18 | Banerjee Subhashis | Sell · S · 10b5-1 | 429 | $12.00 | $5,148 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Bearish signalScored 2026-10-12 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
ARTV presents a deeply concerning financial profile with zero revenue, persistent operating losses, and rapid cash burn that severely undermines any catalytic upside from upcoming clinical data presentations.
The first sentence of the analysis written for ARTV on 2026-10-12 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Bearish signal
Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Supports a bullish reading. Current ratio 8.61 · operating margin 0.0%
Suggested stop 4.55, nearest stored support minus 0.5 ATR(22.3% under the last close). Reward/risk to the next stored resistance is 1.08. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Ebit Margin | 0.0% | -23304.0% | -82.5% | -1183.0% | -3587.7% | |
| Ebitda Margin | 0.0% | -22335.5% | -75.7% | -1159.5% | -3575.3% | |
| Operating Profit Margin | 0.0% | -26805.6% | -91.6% | -1213.3% | -2660.9% | |
| Pretax Profit Margin | 0.0% | -23304.0% | -82.5% | -1183.0% | -3587.7% | |
| Continuous Operations Profit Margin | 0.0% | -23304.0% | -82.7% | -1184.1% | -3587.7% | |
| Net Profit Margin | 0.0% | -23304.0% | -82.7% | -1184.1% | -3587.7% | |
| Bottom Line Profit Margin | 0.0% | -23304.0% | -82.7% | -1184.1% | -3587.7% | |
| Current Ratio | 8.609 | 15.395 | 6.528 | 4.085 | 8.406 | |
| Quick Ratio | 8.609 | 15.395 | 6.528 | 4.085 | 8.406 | |
| Solvency Ratio | -3.875 | -2.444 | -0.095 | -0.209 | -0.277 | |
| Cash Ratio | 2.040 | 3.284 | 4.376 | 4.001 | 8.336 | |
| Price To Earnings Ratio | -1.251 | -1.938 | -10.084 | -3.614 | -2.941 | |
| Price To Earnings Growth Ratio | 0.037 | -0.006 | 0.157 | 0.194 | -0.010 | |
| Forward Price To Earnings Growth Ratio | 0.037 | -0.006 | 0.157 | 0.194 | -0.010 | |
| Price To Earnings Diluted Ratio | -1.251 | -1.938 | -10.084 | -3.614 | -2.941 | |
| Price To Earnings Diluted Growth Ratio | 0.037 | -0.006 | 0.157 | 0.194 | -0.010 | |
| Price To Book Ratio | 0.954 | 1.316 | -1.724 | -1.500 | -2.375 | |
| Price To Sales Ratio | 0.000 | 978.407 | 8.342 | 42.790 | 105.394 | |
| Price To Free Cash Flow Ratio | -1.322 | -4.411 | -5.512 | -3.693 | -12.391 | |
| Price To Operating Cash Flow Ratio | -1.366 | -4.462 | -5.890 | -4.151 | -13.787 | |
| Debt To Assets Ratio | 0.084 | 0.068 | 0.161 | 0.146 | 0.010 | |
| Debt To Equity Ratio | 0.099 | 0.077 | -0.104 | -0.138 | -0.020 | |
| Debt To Capital Ratio | 0.090 | 0.071 | -0.117 | -0.160 | -0.020 | |
| Long Term Debt To Capital Ratio | 0.067 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.191 | 1.123 | -0.649 | -0.946 | -1.912 | |
| Working Capital Turnover Ratio | 0.000 | 0.002 | 0.457 | 0.044 | 0.025 | |
| Operating Cash Flow Ratio | -5.865 | -4.491 | -3.879 | -1.984 | -0.793 | |
| Operating Cash Flow Sales Ratio | 0.000 | -219.251 | -1.416 | -10.308 | -7.644 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.034 | 1.012 | 1.069 | 1.124 | 1.113 | |
| Debt Service Coverage Ratio | -26.567 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | -25.090 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -7.014 | -3.834 | -2.805 | -2.614 | -8.790 | |
| Capital Expenditure Coverage Ratio | -29.668 | -85.720 | -14.558 | -8.069 | -8.877 | |
| Dividend Paid And Capex Coverage Ratio | -29.668 | -85.720 | -14.558 | -8.069 | -8.877 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -1.096 | -3.919 | -9.574 | -2.237 | -0.724 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | ▼-100.0% | ▼-80.0% |
| Ebit Margin | 0.0% | ▲23304.0% | ▲5631.4% |
| Ebitda Margin | 0.0% | ▲22335.5% | ▲5429.2% |
| Operating Profit Margin | 0.0% | ▲26805.6% | ▲6154.3% |
| Pretax Profit Margin | 0.0% | ▲23304.0% | ▲5631.4% |
| Continuous Operations Profit Margin | 0.0% | ▲23304.0% | ▲5631.7% |
| Net Profit Margin | 0.0% | ▲23304.0% | ▲5631.7% |
| Bottom Line Profit Margin | 0.0% | ▲23304.0% | ▲5631.7% |
| Current Ratio | 8.609 | ▼-6.786 | ▲0.004 |
| Quick Ratio | 8.609 | ▼-6.786 | ▲0.004 |
| Solvency Ratio | -3.875 | ▼-1.432 | ▼-2.495 |
| Cash Ratio | 2.040 | ▼-1.243 | ▼-2.367 |
| Price To Earnings Ratio | -1.251 | ▲0.688 | ▲2.715 |
| Price To Earnings Growth Ratio | 0.037 | ▲0.043 | ▼-0.038 |
| Forward Price To Earnings Growth Ratio | 0.037 | ▲0.043 | ▼-0.038 |
| Price To Earnings Diluted Ratio | -1.251 | ▲0.688 | ▲2.715 |
| Price To Earnings Diluted Growth Ratio | 0.037 | ▲0.043 | ▼-0.038 |
| Price To Book Ratio | 0.954 | ▼-0.362 | ▲1.619 |
| Price To Sales Ratio | 0.000 | ▼-978.407 | ▼-226.987 |
| Price To Free Cash Flow Ratio | -1.322 | ▲3.089 | ▲4.144 |
| Price To Operating Cash Flow Ratio | -1.366 | ▲3.096 | ▲4.565 |
| Debt To Assets Ratio | 0.084 | ▲0.015 | ▼-0.010 |
| Debt To Equity Ratio | 0.100 | ▲0.023 | ▲0.117 |
| Debt To Capital Ratio | 0.090 | ▲0.019 | ▲0.117 |
| Long Term Debt To Capital Ratio | 0.067 | ▲0.067 | ▲0.053 |
| Financial Leverage Ratio | 1.191 | ▲0.068 | ▲1.429 |
| Working Capital Turnover Ratio | 0.000 | ▼-0.002 | ▼-0.106 |
| Operating Cash Flow Ratio | -5.865 | ▼-1.373 | ▼-2.462 |
| Operating Cash Flow Sales Ratio | 0.000 | ▲219.251 | ▲47.724 |
| Free Cash Flow Operating Cash Flow Ratio | 1.034 | ▲0.022 | ▼-0.036 |
| Debt Service Coverage Ratio | -26.567 | ▼-26.567 | ▼-21.253 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | -25.090 | ▼-25.090 | ▼-20.072 |
| Operating Cash Flow Coverage Ratio | -7.014 | ▼-3.180 | ▼-2.003 |
| Capital Expenditure Coverage Ratio | -29.668 | ▲56.052 | ▼-0.290 |
| Dividend Paid And Capex Coverage Ratio | -29.668 | ▲56.052 | ▼-0.290 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -1.096 | ▲2.822 | ▲2.414 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $104.9M | $245.6M | $279.4M | $211.0M | $211.0M | |
| Enterprise value | $89.1M | $219.7M | $242.8M | $127.9M | $51.8M | |
| EV / Sales | 0.00x | 875.30x | 7.25x | 25.94x | 25.88x | |
| EV / Op. cash flow | -1.16x | -3.99x | -5.12x | -2.52x | -3.39x | |
| EV / Free cash flow | -1.12x | -3.95x | -4.79x | -2.24x | -3.04x | |
| EV / EBITDA | -1.10x | -3.92x | -9.57x | -2.24x | -0.72x | |
| Net debt / EBITDA | 0.19x | 0.46x | 1.44x | 1.45x | 2.22x | |
| Current ratio | 8.61x | 15.39x | 6.53x | 4.08x | 8.41x | |
| Income quality | 0.92x | 0.84x | 1.65x | 0.86x | 0.21x | |
| Graham net-net | $4 | $7 | -$8 | -$10 | -$6 | |
| Tax burden | 100.0% | 100.0% | 100.3% | 100.1% | 100.0% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Working capital | $99.6M | $176.4M | $67.6M | $79.0M | $143.0M | |
| Invested capital | $116.9M | $196.8M | $92.2M | $106.7M | $147.1M | |
| Return on assets | -64.0% | -27.9% | -26.3% | -43.9% | -42.3% | |
| Operating ROA | -53.2% | -42.8% | -25.8% | -39.5% | -53.5% | |
| Return on tangible assets | -64.0% | -27.9% | -26.3% | -43.9% | -42.3% | |
| Return on equity | -76.3% | -31.3% | 17.1% | 41.5% | 80.8% | |
| Return on invested capital | -74.9% | -33.5% | -31.8% | -53.9% | -35.3% | |
| Return on capital employed | -76.9% | -34.1% | -33.0% | -55.7% | -35.4% | |
| Earnings yield | -80.0% | -23.8% | -9.9% | -27.7% | -34.0% | |
| Free cash flow yield | -75.7% | -22.7% | -18.1% | -27.1% | -8.1% | |
| Capex / Op. cash flow | -3.4% | -1.2% | -6.9% | -12.4% | -11.3% | |
| Capex / Depreciation | 99.6% | 26.4% | 143.8% | 544.0% | 695.2% | |
| Capex / Sales | 0.0% | 255.8% | 9.7% | 127.7% | 86.1% | |
| SG&A / Sales | 0.0% | 6854.6% | 41.5% | 421.3% | 642.6% | |
| R&D / Sales | 0.0% | 20051.0% | 150.0% | 892.0% | 2118.4% | |
| Stock comp / Sales | 0.0% | 2780.9% | 21.1% | 133.5% | 215.1% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 212d | 19d | 39d | 85d | |
| Days payables outstanding | 50d | 0d | 0d | 0d | 0d | |
| Operating cycle | 0d | 212d | 19d | 39d | 85d | |
| Cash conversion cycle | -50d | 212d | 19d | 39d | 85d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-57.3%EV / Sales ▼-100.0%EV / EBITDA ▲+72.0%EV / Op. cash flow ▲+2.831Earnings yield ▼-0.562
Profitability
Return on equity ▼-0.449Return on assets ▼-0.361Return on invested capital ▼-0.415Return on capital employed ▼-0.428Operating ROA ▼-0.105Income quality ▲+0.073Tax burden 0.000
Efficiency
Days sales outstanding ▼-212.311Days payables outstanding n/aOperating cycle ▼-212.311Cash conversion cycle ▼-262.205Capex / Sales ▼-2.558R&D / Sales ▼-200.510
Balance-sheet strength
Current ratio ▼-6.786Net debt / EBITDA ▼-0.268Working capital ▼-76799000.000Invested capital ▼-79869000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▼-50.3%EV / Sales ▼-100.0%EV / EBITDA ▼-51.5%EV / Op. cash flow ▲+2.225Earnings yield ▼-0.459
Profitability
Return on equity ▼-1.571Return on assets ▼-0.218Return on invested capital ▼-0.397Return on capital employed ▼-0.415Operating ROA ▲+0.003Income quality ▲+0.702Tax burden 0.000
Efficiency
Days sales outstanding ▼-85.325Days payables outstanding n/aOperating cycle ▼-85.325Cash conversion cycle ▼-135.219Capex / Sales ▼-0.861R&D / Sales ▼-21.184
Balance-sheet strength
Current ratio ▲+0.203Net debt / EBITDA ▼-2.030Working capital ▼-43403000.000Invested capital ▼-30126000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Recent news
- 2026-10-02 Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at the American College of Rheumatology (ACR) Convergence 2026 Oral presentation highlighting updated clinical data from at least 20 patients with refractory rheumatoid arthritis (RA), 11 patients with Sjögren disease (SjD) and at least five patients with systemic sclerosis (SSc) treated with AlloNK plus rituximab in the ongoing Phase 2a basket trial, all with at least six months of follow-up Poster presentation highlighting deep, consistent B-cell depletion comparable to that observed with CD19 CAR T-cell therapies and a favorable tolerability profile across immune-mediated diseases Poster presentation characterizing the high unmet medical need and low clinical response rates among patients with refractory RA following an inadequate response to at least two distinct classes of biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), a population similar to that being studied in the Phase 3 registrational trial Live webcast on Monday, November 9, 2026 at 8:15 am EST to review Artiva''s presentations, including an in-depth analysis of data from at least 10 patients with refractory RA who have at least six months of follow-up and would meet key eligibility criteria for the Phase 3 registrational trial SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced one oral and two poster presentations at ACR Convergence 2026 featuring updated data from its AlloNK® program and a registry analysis of the high unmet medical need in refractory RA. Artiva will host a live webcast on Monday, November 9, 2026, at 8:15 am EST to review its ACR presentations and updated clinical data from at least 20 patients with refractory RA who have at least six months of follow-up.
- 2026-10-01 Artiva Biotherapeutics Highlights Updated AlloNK® Data in Sjögren Disease Presented at the 17th International Symposium on Sjögren''s Disease (ISSjD 2026) Artiva Biotherapeutics Highlights Updated AlloNK® Data in Sjögren Disease Presented at the 17th International Symposium on Sjögren''s Disease (ISSjD 2026)
- 2026-09-23 Artiva Biotherapeutics Announces Oral Presentation of AlloNK® Clinical Data at the 17th International Symposium on Sjögren''s Disease SAN DIEGO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that updated clinical data will be delivered in an oral presentation at the 17th International Symposium on Sjögren''s Disease (ISSjD 2026), taking place September 29th – October 2nd at the Cité Internationale Universitaire de Paris: Abstract Title: AB-101, an Outpatient-Administered Allogeneic NK Cell Therapy, Combined withRituximab Generates Robust Efficacy Responses in 11 Patients with Sjögren Disease Presenting Author: Guillermo J.
- 2026-09-17 Artiva Biotherapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum SAN DIEGO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that management will participate in a fireside chat at the Stifel 2026 Virtual Immunology and Inflammation Forum on Thursday, September 24, 2026, at 10:00 am EDT.
- 2026-09-08 Artiva Biotherapeutics Provides Update on Planned AlloNK® Data Disclosures and Development Milestones for the Remainder of 2026 Updated clinical data expected in the second half of 2026 from at least 20 patients with refractory rheumatoid arthritis (RA) treated with AlloNK and rituximab in the ongoing company-sponsored Phase 2a basket trial, each with at least six months of follow-up, including at least 10 patients who would meet key eligibility criteria for the Phase 3 registrational trial in refractory RA Updated clinical data expected in the second half of 2026 from at least 10 patients with Sjögren disease (SjD) and at least five patients with systemic sclerosis (SSc), each with at least six months of follow-up Initiating Phase 3 registrational randomized controlled trial evaluating AlloNK® plus rituximab versus rituximab alone in approximately 150 patients with refractory RA, with further updates on site activation and enrollment initiation expected in the second half of 2026 SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today provided an update on anticipated data disclosures and development milestones for its lead program, AlloNK® (also known as AB-101), through year-end 2026.
- 2026-09-02 Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in September SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that management will participate at the following investor conferences: 2026 Cantor Global Healthcare Conference – live fireside chat on Wednesday, September 9, 2026 at 10:20 am EDT H.C.
- 2026-08-26 2,353,304 Shares in Artiva Biotherapeutics, Inc. $ARTV Acquired by 5AM Venture Management LLC 5AM Venture Management LLC acquired a new stake in shares of Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 2,353,304 shares of the company''s stock, valued at approximately $22,827,049,000. Artiva Biotherapeutics accounts for 7.9% of 5AM
- 2026-08-11 Contrasting Artiva Biotherapeutics (NASDAQ:ARTV) & ProQR Therapeutics (NASDAQ:PRQR) ProQR Therapeutics (NASDAQ: PRQR - Get Free Report) and Artiva Biotherapeutics (NASDAQ: ARTV - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability. Valuation and Earnings This table compares ProQR
- 2026-08-06 Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights Clinical, safety and translational data presented at EULAR 2026 reinforced AlloNK®''s potential to drive deep B-cell depletion and meaningful clinical activity, with a tolerability profile supportive of outpatient administration U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to AlloNK plus rituximab for refractory rheumatoid arthritis (RA) Initiating Phase 3 registrational randomized controlled trial evaluating AlloNK plus rituximab versus rituximab alone in approximately 150 refractory RA patients in the second half of 2026 Strong balance sheet with cash, cash equivalents and investments of $349.4 million as of June 30, 2026, expected to fund operations into 2029 SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced financial results for the second quarter ended June 30, 2026, and highlighted recent progress. “The second quarter was transformative for Artiva.
- 2026-07-17 Artiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, July 17, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that the Compensation Committee of its Board of Directors approved new employee inducement grants covering an aggregate of 288,800 restricted stock units (the “Inducement Grants”) for 17 new employees.